{"protocolSection":{"identificationModule":{"nctId":"NCT05920902","orgStudyIdInfo":{"id":"RJ_ASLIS"},"organization":{"fullName":"Ruijin Hospital","class":"OTHER"},"briefTitle":"Arterial Spin Label Depicted Ischemic Stroke Cohort (ASLIS)","officialTitle":"Arterial Spin Label Depicted Ischemic Stroke Cohort (ASLIS)","acronym":"ASLIS"},"statusModule":{"statusVerifiedDate":"2023-02","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-10-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-06-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-02-09","studyFirstSubmitQcDate":"2023-06-24","studyFirstPostDateStruct":{"date":"2023-06-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-06-24","lastUpdatePostDateStruct":{"date":"2023-06-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Ruijin Hospital","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Establish a clinical cohort of acute ischemic stroke patients and find the determinant of the prognosis.","detailedDescription":"1. Enrollment: screening the candidates based on the inclusion and exclusion criteria, and sign the informed consent.\n2. Baseline evaluation: evaluate baseline situation of enrolled candidates.\n3. Inpatient view: view and evaluate enrolled candidates respectively at day 1, 3, 7 and 14 after stroke, and record the results.\n4. Follow-up: view the candidates at 90 days and one year after stroke onset, and record the results.\n5. Data analysis: analyze the results."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["acute ischemia stroke, arterial spin labeling, evaluation"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":true,"targetDuration":"1 Year","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":200,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Acute ischemia stroke","description":"Best medcine treatment. It including antiplatelet drugs, statins, hypotensive drugs, antidiabetics, neurotrophic drugs, butylphthalide, edaravone.","interventionNames":["Other: routine therapy of acute ischemia stroke"]}],"interventions":[{"type":"OTHER","name":"routine therapy of acute ischemia stroke","description":"Routine therapy of acute ischemia stroke based on the guidelines, which generally includes two parts: evaluation and medicine treatment. Evaluation includes peripheral blood test, radiologic examination, electrophysiological examination, ultrasonic examination. Medicine treatment includes drug therapy and rehabilitation.","armGroupLabels":["Acute ischemia stroke"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progressively deterioration in acute phase","description":"Number of participants whose SNOB (Standardised nursing observations for stroke) score at 7 days post ischemia stroke ≤ 2 points compared to baseline, and/or NIHSS score at 7 days post ischemia stroke ≥ 2 points compared to baseline are identified as progressively deterioration in acute phase.","timeFrame":"7 days after ischemia stroke onset"},{"measure":"Bad prognosis of acute ischemia stroke","description":"Number of participants whose mRS (Modified rankin scale) score at 90 days after ischemia \\> 2 are identified as bad prognosis.","timeFrame":"90 days after ischemia stroke onset"}],"secondaryOutcomes":[{"measure":"Recurrent vascular episode","description":"Including transient ischemia attack, intracranial hemorrhage, ischemia stroke","timeFrame":"1 year"},{"measure":"Recurrent artery stenosis","description":"Degree of artery stenosis at one year after stenting \\> 50%","timeFrame":"one year after stenting"},{"measure":"Unhealthy status","description":"Any dimension in EQ-5D-3L (the generic three-level EuroQol five-dimensional questionnaire) score ≥ 2","timeFrame":"1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age 30-90, no gender restrictions.\n2. Onset of disease ≤7 days.\n3. Meet either of the following two conditions:\n\n   ① Transient ischemic attack (TIA)\n\n   ② Ischemia stroke (IS) Note: Acute IS diagnosis criteria: sudden and persistent focal or widespread neurological dysfunction, excluding other non-vascular causes of brain dysfunction (such as brain infection, head injury, brain tumor, epilepsy, severe metabolic diseases, or degenerative neurological diseases), confirmed by image as new IS. TIA diagnosis criteria: sudden and reversible focal neurological or retinal ischemic deficit caused by a reversible ischemia, usually lasting less than 24 hours, with no evidence of new IS on imaging, and excluding other non-ischemic causes (such as brain infection, head injury, brain tumor, epilepsy, severe metabolic diseases, or degenerative neurological diseases).\n4. Signed informed consent\n\nExclusion Criteria:\n\n1. Clear cause of ischemic stroke other than atrial fibrillation.\n2. Other ischemic strokes with a clear cause.\n3. Presence of non-vascular intracranial disease.\n4. Presence of severe systemic diseases.\n5. Pregnancy or lactation.\n6. Unable to tolerate or cooperate with MRI examination.\n7. Unable to comply with follow-up due to geographical or other reasons.","healthyVolunteers":true,"sex":"ALL","genderBased":true,"minimumAge":"30 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Who sufferred acute ischemia stroke and be admitted to the ward of Ruijin Hospital, and meets the inclusion criteria, and does not meet the exclusion criteria.","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Wei Jin, PhD. MD.","role":"CONTACT","phone":"18916705082","email":"jw12170@rjh.com.cn"}],"overallOfficials":[{"name":"Wei Jin, PhD. MD.","affiliation":"Ruijin Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Ruijin hospital","status":"RECRUITING","city":"Shanghai","state":"Shanghai","zip":"200000","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Results of the research will be shared in the form of paper publishing. Other researchers who wants to know the details can contact with the PI."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M1831","name":"Edaravone","relevance":"LOW"},{"id":"M3967","name":"Antihypertensive Agents","relevance":"LOW"},{"id":"M9744","name":"Hypoglycemic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M20845","name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","relevance":"LOW"},{"id":"M352286","name":"3-n-butylphthalide","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnAg","name":"Antihypertensive Agents"},{"abbrev":"Hypo","name":"Hypoglycemic Agents"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"Lipd","name":"Lipid Regulating Agents"}]}},"hasResults":false}